INTELLIGENT OLIVE OIL NANOCAPSULAS FOR ORAL ADMINISTRATION OF PHARMACOS AGAINST PANCREATICAS STEM CELLS (Q3136062): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): PANCREAS CANCER (PC) IS THE FOURTH CAUSE OF CANCER-RELATED DEATH AND REMAINS INTRACTABLE, WITH A VERY POOR SURVIVAL RATE AT AGE 5. WHEN DIAGNOSED, MORE THAN 80 % OF PATIENTS HAVE ADVANCED DISEASE, WHICH DOES NOT ALLOW SURGICAL RESECTION. FACTORS THAT CONTRIBUTE TO THEIR LETHALITY INCLUDE CANCEROUS STEM CELLS (CSCS), A SMALL SUBPOBLACION WITHIN THE TUMORS RESPONSIBLE FOR CANCER INITIATION, GROWTH, RECURRENCE, AND RESISTANCE TO CHEMOTHERAPY. THEY...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
INTELLIGENT OLIVE OIL NANOCAPSULAS FOR ORAL ADMINISTRATION OF PHARMACOS AGAINST PANCREATICAS STEM CELLS | |||
Revision as of 13:14, 12 October 2021
Project Q3136062 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | INTELLIGENT OLIVE OIL NANOCAPSULAS FOR ORAL ADMINISTRATION OF PHARMACOS AGAINST PANCREATICAS STEM CELLS |
Project Q3136062 in Spain |
Statements
87,120.0 Euro
0 references
108,900.0 Euro
0 references
80.0 percent
0 references
1 January 2016
0 references
31 December 2019
0 references
UNIVERSIDAD DE GRANADA
0 references
37°10'24.60"N, 3°35'58.31"W
0 references
18087
0 references
EL CANCER DE PANCREAS (PC) ES LA CUARTA CAUSA DE MUERTE RELACIONADA CON EL CANCER Y SIGUE SIENDO INTRATABLE, CON UNA TASA DE SUPERVIVENCIA MUY POBRE A LOS 5 AÑOS. CUANDO SE DIAGNOSTICA, MAS DEL 80% DE LOS PACIENTES TIENEN LA ENFERMEDAD AVANZADA, LO CUAL NO PERMITE SU RESECCION QUIRURGICA. ENTRE LOS FACTORES QUE CONTRIBUYEN A SU LETALIDAD SE INCLUYEN LAS CELULAS MADRE CANCERIGENAS (CSCS), UNA PEQUEÑA SUBPOBLACION DENTRO DE LOS TUMORES RESPONSABLE DE LA INICIACION DEL CANCER, EL CRECIMIENTO, LA RECIDIVA Y RESISTENCIA A LA QUIMIOTERAPIA. ESTAN REGULADAS POR LAS RUTAS HEDGEHOG, NOTCH, WNT, BMI-1 O PTEN. LAS CSC PANCREATICAS (PCSCS) SE CARACTERIZAN POR LA SOBREEXPRESION DE MARCADORES DE SUPERFICIE ESPECIFICOS CD24, CD44, ESA, C-MET O CXCR4, UNA ALTA ACTIVIDAD ALDH, LA EXCLUSION DEL COLORANTE HOECHST Y UN POTENCIAL ALTAMENTE TUMORIGENICO EN XENOINJERTOS. LAS ESTRATEGIAS TERAPEUTICAS DIRIGIDAS A LA MODULACION DE ESTAS VIAS O HACIA MARCADORES DE SUPERFICIE DE PCSCS PUEDEN TENER IMPORTANTES APLICACIONES CLINICAS. SIN EMBARGO, UN FACTOR LIMITANTE ES LA DIFICULTAD DE AISLAR Y MANTENER SUS CARACTERISTICAS ¿STEM¿. RECIENTEMENTE, NUESTRO GRUPO DE INVESTIGACION HA PATENTADO UN METODO Y MEDIO DE CULTIVO [P201400666] DE AISLAMIENTO Y ENRIQUECIMIENTO DE SUBPOBLACIONES DE CSCS EN LINEAS ESTABLECIDAS Y CULTIVOS PRIMARIOS DURANTE DOS SEMANAS SIN REALIZAR NINGUN PROCESAMIENTO ADICIONAL. ESTO PERMITE LA SELECCION DE ESTRATEGIAS ANTITUMORALES DIRIGIDAS. ADEMAS, HEMOS DEMOSTRADO EL MECANISMO DE ACCION Y LAS PROPIEDADES ANTITUMORALES FRENTE A RUTAS DE CSC DE NUEVOS COMPUESTOS NATURALES Y SINTETICOS. TAMBIEN, EN COLABORACION CON MIEMBROS DE SUBPROYECTO 1, HEMOS DISEÑADO Y EVALUADO LA EFICACIA DE NANOCAPSULAS DE ACEITE DE OLIVA FUNCIONALIZADAS (LNCS). DADO QUE ESTAS LNCS PERMITEN EL TRANSPORTE DE FARMACOS UTILIZADOS CLINICAMENTE EN CONCENTRACIONES MAS BAJAS Y MENOS TOXICAS Y LA UNION DE ANTICUERPOS EN SU SUPERFICIE, PARTIMOS DE LA HIPOTESIS DE QUE NUEVAS LNCS INTELIGENTES CARGADAS CON FARMACOS ANTI-CSC SERAN BIODISPONIBLES POR VIA ORAL E INHIBIRAN EL CRECIMIENTO TUMORAL Y LA METASTASIS EN UN MODELO PRECLINICO DE PC._x000D_ OBJETIVOS: I) EVALUAR LA CAPACIDAD IN VITRO DE LNCS PARA PASAR LA BARRERA GASTROINTESTINAL Y SU BIODISPONIBILIDAD ORAL IN VIVO; II) ESTUDIAR EL MECANISMO MOLECULAR DE NUEVOS COMPUESTOS NATURALES Y SINTETICOS FRENTE A PCSCS AISLADAS DE LINEAS CELULARES Y DE MUESTRAS DE PACIENTES; III) EVALUAR LA EFICACIA IN VITRO E IN VIVO Y TOXICIDAD DE LNCS FUNCIONALIZADAS Y CARGADAS CON FARMACOS FRENTE PCSCS; IV) EXAMINAR LA BIODISTRIBUCION, SEGURIDAD Y EFICACIA DE LNCS INTELIGENTES EN XENOINJERTOS SUBCUTANEOS Y ORTOTOPICOS DERIVADOS DE PACIENTES CON PC. _x000D_ RETO: LOS TRATAMIENTOS ACTUALES CONTRA EL PC SON INEFICIENTES, TOXICOS PARA LAS CELULAS NORMALES Y NO LOGRAN MATAR SELECTIVAMENTE LAS PCSCS. HAY MUY POCOS ESTUDIOS CON NCS USADAS POR VIA ORAL PARA LA LIBERACION SISTEMICA DE FARMACOS SELECTIVOS FRENTE AL CANCER COMO ALTERNATIVA A LA VIA INTRAVENOSA. EN ESTE PROYECTO PROPONEMOS EVALUAR Y VALIDAR NCS DE ACEITE DE OLIVA ORALES DIRIGIDAS COMO HERRAMIENTAS TERAPEUTICAS FRENTE A PCSCS USANDO XENOINJERTOS DERIVADOS DEL PACIENTE CON PC._x000D_ NUESTRA PRIORIDAD ES LA TRASLACION DE LA INVESTIGACION BASICA A LA APLICACION CLINICA, CON UN EQUIPO INTERDISCIPLINAR COMPUESTO POR INVESTIGADORES BASICOS Y CLINICOS, Y EL APOYO DE TRES EPOS. ESPERAMOS CREAR NUEVAS COLABORACIONES INTERNACIONALES A TRAVES DE REDES ESPECIALIZADAS (COST) Y APLICAR AL PROGRAMA DE FINANCIACION H2020. (Spanish)
0 references
PANCREAS CANCER (PC) IS THE FOURTH CAUSE OF CANCER-RELATED DEATH AND REMAINS INTRACTABLE, WITH A VERY POOR SURVIVAL RATE AT AGE 5. WHEN DIAGNOSED, MORE THAN 80 % OF PATIENTS HAVE ADVANCED DISEASE, WHICH DOES NOT ALLOW SURGICAL RESECTION. FACTORS THAT CONTRIBUTE TO THEIR LETHALITY INCLUDE CANCEROUS STEM CELLS (CSCS), A SMALL SUBPOBLACION WITHIN THE TUMORS RESPONSIBLE FOR CANCER INITIATION, GROWTH, RECURRENCE, AND RESISTANCE TO CHEMOTHERAPY. THEY ARE REGULATED BY THE HEDGEHOG, NOTCH, WNT, BMI-1 OR PTEN ROUTES. PANCREATIC CSCS (PCSCS) ARE CHARACTERISED BY THE OVEREXPRESSION OF SPECIFIC SURFACE MARKERS CD24, CD44, THAT, C-MET OR CXCR4, A HIGH ALDH ACTIVITY, THE EXCLUSION OF HOECHST DYE AND A HIGHLY TUMORIGENIC POTENTIAL IN XENOGRAFTS. THERAPEUTIC STRATEGIES AIMED AT MODULATING THESE PATHWAYS OR TOWARDS PCSCS SURFACE MARKERS CAN HAVE IMPORTANT CLINICAL APPLICATIONS. HOWEVER, A LIMITING FACTOR IS THE DIFFICULTY OF ISOLATING AND MAINTAINING ITS CHARACTERISTICS STEM. RECENTLY, OUR RESEARCH GROUP HAS PATENTED A METHOD AND MEANS OF CULTIVATION [P201400666] OF ISOLATION AND ENRICHMENT OF SUBPOPULATIONS OF CSCS IN ESTABLISHED LINES AND PRIMARY CROPS FOR TWO WEEKS WITHOUT PERFORMING ANY ADDITIONAL PROCESSING. THIS ALLOWS THE SELECTION OF TARGETED ANTITUMOUR STRATEGIES. IN ADDITION, WE HAVE DEMONSTRATED THE MECHANISM OF ACTION AND ANTITUMOUR PROPERTIES AGAINST CSC PATHWAYS OF NEW NATURAL AND SYNTHETIC COMPOUNDS. ALSO, IN COLLABORATION WITH SUBPROJECT MEMBERS 1, WE HAVE DESIGNED AND EVALUATED THE EFFECTIVENESS OF FUNCTIONALISED OLIVE OIL NANOCAPSULAS (LNCS). Given that these LNCs allow the transport of pharmacies clinically used in more low and more toxic conditions and the union of anti-domestic people in their superfice, we start from the hypothesis of which new intelligent LNCs loaded with anti-CSC pharmacies will be biodisponable by ORAL VIA and INHIBIRAN TUMORAL GROWING AND METASTASIS in a preclinical model of PC._x000D_ OBJECTIVES: ASSESS THE IN VITRO ABILITY OF NSCL TO PASS THE GASTROINTESTINAL BARRIER AND ITS ORAL BIOAVAILABILITY IN VIVO; TO STUDY THE MOLECULAR MECHANISM OF NEW NATURAL AND SYNTHETIC COMPOUNDS VERSUS SCSCS ISOLATED FROM CELL LINES AND PATIENT SAMPLES; TO EVALUATE THE IN VITRO AND IN VIVO EFFICACY AND TOXICITY OF FUNCTIONALISED AND PHARMACO-CHARGED NSCLS AGAINST SCSCS; IV) EXAMINE BIODISTRIBUTION, SAFETY AND EFFICACY OF INTELLIGENT NSCLS IN SUBCUTANEOUS XENOGRAFTS AND ORTOTOPICOS DERIVED FROM PC PATIENTS. _x000D_ challenge: CURRENT TREATMENTS AGAINST PC ARE INEFFICIENT, TOXIC TO NORMAL CELLS AND FAIL TO SELECTIVELY KILL SCSCS. THERE ARE VERY FEW STUDIES WITH NCS USED BY ORAL VIA FOR THE SYSTEMIC RELEASE OF SELECTIVE CANCER PHARMACOS AS AN ALTERNATIVE TO INTRAVENOUS PATHWAY. In this project we propose to evaluate and valiate OIL OIL NCS DIRIGIDED AS TERAPEUTIC TOOLS FENT TO PCSCS USED XENOINJERTS DERIVED PATIENT WITH PC._x000D_Our PRIORITY is the translation of basic research into CLINICAL APPLICATION, with an INTERDISCIPLINATE TEAM BY BASIC AND CLINICAL RESEARCHERS, AND THE SUPPORT OF THREE EPOS. WE HOPE TO CREATE NEW INTERNATIONAL COLLABORATIONS THROUGH SPECIALISED NETWORKS (COST) AND APPLY TO THE H2020 FINANCING PROGRAM. (English)
12 October 2021
0 references
Granada
0 references
Identifiers
MAT2015-63644-C2-2-R
0 references